Poor treatment tolerance in head and neck cancer patients with low muscle mass
Marco A. Mascarella(Jewish General Hospital), Shaum Sridharan(University of Pittsburgh), Marie‐Jeanne Kergoat(Université de Montréal), Mario G. Solari(University of Pittsburgh Medical Center), Lauren Gardiner(University of Pittsburgh Medical Center), Umamaheswar Duvvuri(City University of New York), Varun Vendra(University of Pittsburgh Medical Center), Robert L. Ferris(University of Pittsburgh), Terral Patel(University of Pittsburgh Medical Center), Seungwon Kim(UPMC Hillman Cancer Center), Katie Traylor(University of Pittsburgh Medical Center), Mark Kubik(University of Pittsburgh), Carl H. Snyderman(University of Pittsburgh Medical Center)
Cited by 20
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590